Contrast-enhanced ultrasound with a novel nanoparticle contrast agent for clinical diagnosis in patients with non-small cell lung cancer

Abstract

Abstract. Non-small cell lung cancer (NSCLC) initiates in the non-small cells of the lung and is one of the most common types of human cancer. It is known for its rapid growth, easy migration, invasion and reoccurrence, and has the highest incidence rate of all types of cancer. Early detection of NSCLC is difficult to achieve and this is the primary reason for low survival rates in NSCLC. Contrast-enhanced ultrasound is the most common application for evaluating patients diagnosed with NSCLC. In the present study, a contrast-enhanced ultrasound combined with nanoparticles was performed with the aim of identifying patients with NSCLC at an early stage. The present study evaluated the effectiveness of administering a nanoparticle contrast agent through respiration in combination with enhanced ultrasound at improving image quality compared with traditional ultrasound. This maybe a novel method of detecting early-stage tumors in patients. There are numerous benefits to conducting diagnoses of NSCLC using contrast-enhanced ultrasound. It is a non-invasive imaging modality, induces little pain, has a low cost, an extensive range and produces high-resolution images. This means that it is safer and more beneficial to use in patients with NSCLC than conventional imaging examinations, including X-ray and bronchoscopy. Furthermore, the nanoscale microbubble contrast agent containing liposome-encapsulated epidermal growth factor receptor was inhaled by nebulization, which may lead to an enhanced ultrasound image. The sensitivity of contrast-enhanced ultrasound was investigated in mice with early stage NSCLC. The results indicated that ultrasound administrated with nanoscale microbubble enhanced sensitivity and improved image quality compared with simple ultrasound. Furthermore, enhanced ultrasound resulted in a reliable and sensitive assessment of tumor mass in early-stage tumors. Altogether, contrast-enhanced ultrasound facilitated the efficient detection of NSCLC in patients in situ at an early stage. This protocol improved the understanding of the pathophysiology of NSCLC and may be applied in the detection of early-stage tumors in patients suspected of having cancer.

Analysis of the Exposure of Organisms to the Action of Nanomaterials

“…As the Raman imaging technique develops and its sensitivity increases, it is anticipated that imaging of nanocarrier placement in living systems in real time will be possible in the future. Nanoparticles are used in contrast agents due to their biocompatibility, high X-ray absorption coefficient and the ability to target a specific pathological tissue [63,64]. In addition, the nanoparticle contrast agent administered during the study improves the quality and resolution of the image, which allows earlier detection of lesions in the body.…”

Role of Gd2O3‑doped carbon‑11‑choline‑lenvatinib nanoparticles contrast agent PET/CT in the diagnosis of patients with lung cancer

“…It has been reported that developing multimodal contrast agent would enhance the diagnostic accuracy of PET/CT, as well as increase the diagnostic accuracy sensitivity in patients with lung cancer (23). A previous study reported that contrast-enhanced ultrasound with a novel nanoparticle contrast agent increases the diagnostic efficacy in patients with NSCLC (24). In addition, another study reported a composite nano-system composed of gadolinium-doped mesoporous silica nanoparticles and gold nanoparticles, which can be used as an efficient contrast agent for in vivo cancer imaging (25).…”

A literature review on multimodality molecular imaging nanoprobes for cancer detection

“…both imaging and therapeutic purposes. Li et al [11] used multi-targeted tyrosine kinase inhibitor Lenvatinib which covalently bound with the superparamagnetic iron oxide nanoparticles (SPIONs) to improve US image quality. They have reported that contrast-enhanced ultrasound improved the imaging quality and diagnostic accuracy of an early stage of non-small cell lung cancer (NSCLC).…”